AJTR Copyright © 2009-present, All rights reserved. Published by e-Century Publishing Corporation, Madison, WI 53711
Am J Transl Res 2013;5(2):132-138

Review Article
Gene expression profiling in breast cancer

Belisario A Arango, Celine L Rivera, Stefan Glück

University of Miami/Sylvester Comprehensive Cancer Center, Miami, FL, USA

Received November 30, 2012; Accepted February 17, 2013; Epub March 28, 2013; Published April 8, 2013

Abstract: In recent years, molecular research has translated into remarkable changes of breast cancer
diagnostics and therapeutics. Molecular tests such as the 21 gene expression test (Oncotype DXTM) and 70
gene microarray test (MammaPrint®) have revolutionized the predictive and prognostic tools in the clinic. By
stratifying the risk of recurrence for patients, the tests are able to provide clinicians with more information on the
treatment outcomes of using chemotherapy, HER2 targeted therapy or endocrine therapy or the combination of
the therapies for patients with particular genetic expressions. However, it is still questionable for clinical
applications as some areas remain unclear and that the true benefit still needs prospective evaluation. Such
studies are under way and are anxiously awaited. In this paper, the limitation of the molecular tests are
discussed. As we are moving towards personalized medicine, molecular profiling will not only result in better
outcomes but in a certain proportion of patients, likely will spare unnecessary use of cytotoxic compounds and
reduce the cost to the health care systems (AJTR1211011).

Keywords: Early breast cancer, gene profiling, predictive and prognostic power

Address correspondence to: Dr. Stefan Glück, Department of Medicine, Division of Hematology/Oncology,
Sylvester Comprehensive Cancer Center, University of Miami, Leonard M. Miller School of Medicine, Miami, FL,
USA. Phone: 305-243-1542; E-mail: SGluck@med.miami.edu